A Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Effects of Single Oral Doses of NSA-789 on Auditory P50 Suppression in Nonsmoking Patients With Stabilized Schizophrenia.
Phase of Trial: Phase I
Latest Information Update: 23 Jul 2009
At a glance
- Drugs NSA 789 (Primary)
- Indications Schizophrenia
- Focus Pharmacodynamics
- 23 Jul 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 13 May 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 13 May 2009 Additional location (USA) identified as reported by ClinicalTrials.gov.